<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638858</url>
  </required_header>
  <id_info>
    <org_study_id>Lucentis_DME_ERG</org_study_id>
    <secondary_id>2011-002202-70</secondary_id>
    <nct_id>NCT01638858</nct_id>
  </id_info>
  <brief_title>Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)</brief_title>
  <official_title>A Prospective, Non-randomized, Mono-center, Cohort Study of Evaluate the Effects of 0.5mg Intraocular Ranibizumab (Lucentis)Injections on Retinal Function in Patients With Diabetic Macular Edema (DME) During Twelve Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Luebeck</source>
  <brief_summary>
    <textblock>
      In this prospective, open-label clinical study is to investigate the behavior of the retinal
      functions during development of diabetic macular disease (DME) under the influence of
      Lucentis. Measurements with the multifocal electroretinogram (ERG) and microperimetry is used
      here as an objective criteria to information about the retinal function obtain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Main outcome measures are the changes of retinal function of the macula monitored by multifocal-ERG as measured 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Main outcome measures are the changes of retinal function of the macula monitored by multifocal-ERG as measured 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to document changes in best corrected visual acuity measured on 4 meters</measure>
    <time_frame>12 months</time_frame>
    <description>to document changes in best corrected visual acuity measured on 4 meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to document changes in microperimetry</measure>
    <time_frame>12 months</time_frame>
    <description>to document changes in microperimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to document changes in optical coherence tomography (OCT)</measure>
    <time_frame>12 months</time_frame>
    <description>to document changes in optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Lucentis (Ranibizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis (Ranibizumab)</intervention_name>
    <description>Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry</description>
    <arm_group_label>Lucentis (Ranibizumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diabetic macular edema with center involvement in at least one eye

          2. patients with a central retinal thickness

          3. patients with a BCVA of 78-24 EDTRS letters

          4. decrease in vision is due to DME and not due to other causes, in the opinion of the
             investigator

          5. Type 1 or type 2 diabetes mellitus diagnosed 2 years prior to screening

        Exclusion Criteria:

          1. history or evidence of severe cardiac disease

          2. clinical or medical history uncontrolled hypertension or diabetes

          3. of unstable angina, acute coronary syndrome, myocardial infarction or
             revascularization with 6 months

          4. ventricular tachyarrhythmias requiring ongoing treatment

          5. history or evidence clinically significant peripheral vascular disease, such a
             intermittent claudication or prior amputation

          6. clinically significant impaired renal or hepatic function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Grisanti, M.D. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Luebeck - Department of Ophthalmology: Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Luebeck - Department of Ophthalmology</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uksh.de/Augenklinik_Lübeck/index.html</url>
    <description>Link Text: University of Lübeck - Department of Ophthalmology - Germany</description>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Dr. Matthias Lueke</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

